BoehringerBoehringer drops inhaled gene therapy for cystic fibrosisSetback for Boehringer Ingelheim: the company has halted development of its inhaled gene therapy BI 3720931 for cystic fibrosis after a phase 1/2 trial failed to deliver efficacy data supporting further … more ➔
Bayer AGBayerUS settlement: Has Bayer untied the Monsanto knot?Years of uncertainty surrounding the numerous pending lawsuits against Bayer’s Monsanto unit could now be brought to an end through a costly but capped court settlement. Under the proposed agreement, … more ➔
depressionCompass Pathways clears second phase III hurdle for psilocybin in treatment-resistant depressionThe share price of London-based Compass Pathways soared over 30% on Tuesday after the company reported that its synthetic psilocybin formulation COMP360 had met the primary endpoint in the second of … more ➔
Unsplash+fundingCubaseBio secures €5.9m to scale 3D spatial transcriptomicsSwedish startup CubaseBio has raised €5.9 million in blended financing to advance its next-generation 3D spatial transcriptomic technology. Of that total, €3.9 million comes from private capital. … more ➔
NeurologyNewron secured €38m to test a potential new class in schizophreniaNewron Pharmaceuticals has secured up to €38mn to advance Phase III trials of evenamide, a drug that, if successful, could represent one of the first circuit-modulating therapies in schizophrenia. more ➔
GrantBiotech Beactica and research institute LISCO secured €2.5M to advance glioblastoma therapy to the clinicThe European Innovation Council (EIC) has funded the collaborative GLIOBREAK project, bringing together Swedish biotech Beactica Therapeutics and the Belgian KU Leuven Institute for Single-Cell Omics … more ➔
Getty Images for Unsplash+migraineLundbeck’s migraine drug hits phase II goal, though IV-only path narrows commercial prospectsDenmark-based Lundbeck has reported positive top-line results from the intravenous arm of its phase IIb PROCEED trial of bocunebart (Lu AG09222) in migraine prevention, putting the neuroscience specialist … more ➔
Immunic/Nela Dornermultiple sclerosisImmunic secured US$400 million to conclude phase 3 MS program and prepare for launchA late-week surprise from Munich-based Immunic, Inc. (listed on Nasdaq as IMUX): the company has launched a follow-on private placement of up to US$400 million and expects to close the financing later … more ➔
ApprovalAmgen wins European approval to challenge argenx and UCB for autoimmune marketThe European Commission has approved Amgen’s Uplizna in generalized myasthenia gravis, moving the big biotech into a market served by argenx, Johnson & Johnson and UCB. more ➔
RoyaltiesGENFIT to receive $20M milestone from Ipsen as Iqirvo tops $200M in first full yearFrench biotech GENFIT will receive a $20 million commercial milestone payment after Ipsen reported $208 million in full-year 2025 net sales of Iqirvo in primary biliary cholangitis, surpassing the $200 … more ➔
Bayer AG
Unsplash+
Getty Images for Unsplash+
Immunic/Nela Dorner
